Cargando…
The Related Metabolic Diseases and Treatments of Obesity
Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chroni...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498506/ https://www.ncbi.nlm.nih.gov/pubmed/36141228 http://dx.doi.org/10.3390/healthcare10091616 |
_version_ | 1784794776050073600 |
---|---|
author | Yang, Ming Liu, Shuai Zhang, Chunye |
author_facet | Yang, Ming Liu, Shuai Zhang, Chunye |
author_sort | Yang, Ming |
collection | PubMed |
description | Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities. |
format | Online Article Text |
id | pubmed-9498506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94985062022-09-23 The Related Metabolic Diseases and Treatments of Obesity Yang, Ming Liu, Shuai Zhang, Chunye Healthcare (Basel) Review Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities. MDPI 2022-08-25 /pmc/articles/PMC9498506/ /pubmed/36141228 http://dx.doi.org/10.3390/healthcare10091616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yang, Ming Liu, Shuai Zhang, Chunye The Related Metabolic Diseases and Treatments of Obesity |
title | The Related Metabolic Diseases and Treatments of Obesity |
title_full | The Related Metabolic Diseases and Treatments of Obesity |
title_fullStr | The Related Metabolic Diseases and Treatments of Obesity |
title_full_unstemmed | The Related Metabolic Diseases and Treatments of Obesity |
title_short | The Related Metabolic Diseases and Treatments of Obesity |
title_sort | related metabolic diseases and treatments of obesity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498506/ https://www.ncbi.nlm.nih.gov/pubmed/36141228 http://dx.doi.org/10.3390/healthcare10091616 |
work_keys_str_mv | AT yangming therelatedmetabolicdiseasesandtreatmentsofobesity AT liushuai therelatedmetabolicdiseasesandtreatmentsofobesity AT zhangchunye therelatedmetabolicdiseasesandtreatmentsofobesity AT yangming relatedmetabolicdiseasesandtreatmentsofobesity AT liushuai relatedmetabolicdiseasesandtreatmentsofobesity AT zhangchunye relatedmetabolicdiseasesandtreatmentsofobesity |